
Professor Roy Taylor discusses the results of the DiRECT trial and the implications for type 2 diabetes remission in the context of GLP-1 medications.
Professor Roy Taylor returns, three years after his first appearance, with the five-year DiRECT trial results and a clear-eyed assessment of where diet-driven type 2 diabetes remission stands in the GLP-1 era. The evidence is now solid: type 2 diabetes is, for many, a reversible condition of excess fat in the liver and pancreas. But keeping it in remission demands keeping the weight off, and the new generation of weight loss drugs comes with marketing claims that Roy says have no evidence behind them. What We Cover: The Twin Cycle Hypothesis and personal fat threshold Five-year DiRECT data: durable remission, halved hospital admissions, fewer cancers Why regaining the weight means the diabetes returns GLP-1s: what they genuinely do, and what's marketing The muscle loss panic, put in perspective Gestational diabetes and pre-pregnancy weight Whether you have type 2 diabetes, care for someone who does, or simply want to understand one of the biggest shifts in modern medicine, this conversation delivers. To learn more about Professor Roy Taylor's work, visit his research site at Newcastle University or read his book Life Without Diabetes. Clinicians can also explore…
Explore listener stats, chart rankings, contacts and more on the The Proof with Simon Hill podcast page.